Aspire Biopharma converts ~$1.75M debt from PowerUp sponsors into common stock

Aspire Biopharma Holdings, Inc.

Exchanged ~$1.75M debt for common stock at closing price less $0.01/share; holders can submit up to 4 exchange notices by Jan 31, 2026.
Each exchange notice limited to 30% of outstanding balance; shares are freely tradeable without restrictive legends.
Upon a financing over $3M, company may repay debt; holder can elect 25% of outstanding balance from proceeds.
Exchange exempt under Section 3(a)(9) of Securities Act; debt originated from 2024 subscription agreements with PowerUp sponsors.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aspire Biopharma Holdings, Inc. entered into Exchange Agreements with certain holders of the Company’s debt valued at approximately $1.75 million (effective 2026-01-01).

Action: entry
Counterparty: certain holders of the Company’s debt
Value: approximately $1.75 million
Effective: 2026-01-01

Exact text from the filing

On January 1, 2026, the Company entered into Exchange Agreements (the “Exchange Agreements”) with certain holders of the Company’s debt (the “Holders”) to exchange approximately $1.75 million in debt for shares (the “Exchange Shares’) of the Company’s common stock (the “Exchange”).

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

Aspire Biopharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-000518

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.